Mitem Pharma: French Pharmaceutical Laboratory
Founded in 2016, Mitem Pharma is a pharmaceutical company specializing in the revitalization, development, and commercialization of drugs of major therapeutic interest used in the treatment of serious illnesses.
A Strong Strategic Positioning
Drugs of major therapeutic interest are mature, high-margin products. Often abandoned by large pharmaceutical companies—which focus on innovation and launching new patent-protected products—these market segments also attract little interest from generic drug specialists.
The company has a hybrid positioning, relying both on the development of generics and the acquisition of original (branded) drugs that are not threatened by generic competition. It is also supported by health authorities, key opinion leaders, specialist physicians, and patient associations.
Mitem Pharma’s revenue model is based on high and secure margins, along with a very high cash conversion rate. Drug prices are set in agreement with health authorities, providing visibility on sales. Margins are negotiated directly with drug manufacturers, and distribution costs are negotiated with local distributors and wholesalers.
A Clear Societal Importance
Mitem Pharma plays a vital role in society by ensuring access to medications whose discontinuation could be life-threatening or significantly reduce patients’ chances of survival.
The company also strives to integrate sustainable practices throughout the product lifecycle. Aware that its supply chain represents a significant portion of its greenhouse gas emissions, Mitem Pharma has initiated a carbon footprint assessment with a consulting firm, prioritizes European suppliers, and conducts additional audits to evaluate social and environmental impacts, particularly in countries such as India and China.
